Latest Breaking News On - China health authority - Page 1 : vimarsana.com

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

David deluciaDeyaa adibSimon millerGlobenewswire incCorporate communicationsFibrogen incExchange commissionDrug administrationRegeneron pharmaceuticalsChina health authorityChief medical officerInvestigational new drugSupplemental new drug applicationInvestor inquiriesInvestor relationsMedia inquiries

FibroGen to Report First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Meichiel keenanDavid deluciaFibrogen incCorporate communicationsChina health authorityAudio webcastSupplemental new drug applicationChina healthInvestor relations

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMeichiel keenandirectorRahul aggarwalDavid deluciaDeyaa adibCorporate communicationsFibrogen incExchange commissionDrug administrationAmerican society for clinical oncologyChina health authorityFortis therapeutics sponsored phaseChief medical officerCalifornia san franciscoLead investigatorAmerican society

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDeyaa adibMeichiel keenanDavid deluciaRahul aggarwalFibrogen incExchange commissionDrug administrationChina health authorityCorporate communicationsAmerican society for clinical oncologyFortis therapeutics sponsored phaseChief medical officerCalifornia san franciscoLead investigatorAmerican society

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMeichiel keenanDavid deluciaDeyaa adibRahul aggarwalExchange commissionDrug administrationAmerican society for clinical oncologyChina health authorityCorporate communicationsFibrogen incGen announces topline resultsMetastatic castration resistant prostateFortis therapeutics sponsored phaseChief medical officerCalifornia san francisco